Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The American Journal of Medicine, 134(2), 146-154
One individual per group was euthanized before addressing the next animal in each group to render differences arising from the time of day at euthanization (e.g., cecal mass changes resulting from differences in time post-food consumption) comparable across all groups
Glucagon-like peptide-1 receptor agonists gained approval as drugs to treat diabetes and obesity starting in the 2000s
This established mechanism provides a baseline of proven efficacy while the additional receptor targets amplify the overall effect
The occurrence of GI disorders is common in people treated with GLP-1R agonists [23, 24] and can be linked to the central effects of GLP-1R agonism and delayed gastric emptying [25, 26]
Copyright The Nations Health, American Public Health Association
